GLS inhibitors have received attention as an adjuvant drug to more traditional chemotherapy in other cancers too, and telaglenastat is generally well tolerated.265, 266, 267, 268 In advanced/metastatic renal cell carcinoma (RCC), telaglenastat in combination with everolimus (a mammalian target of rapamycin[mTOR] inhibitor269) improved PFS268, but did not have a similar effect when paired with cabozantinib (a tyrosine kinase inhibitor270). Here, MTOR is linked to cancer.